Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells
2006 ◽
Vol 12
(19)
◽
pp. 5869-5878
◽
2014 ◽
Vol 10
(3)
◽
pp. 1519-1524
◽
2020 ◽
Vol 185
◽
pp. 111748
◽
1986 ◽
Vol 83
(24)
◽
pp. 9768-9772
◽